

107823, 682

=> d his

(FILE 'HOME' ENTERED AT 18:12:15 ON 01 MAR 2007)

FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH, LIFESCI' ENTERED AT 18:12:37 ON 01 MAR 2007

L1 136235 S ADENOVIRAL(W) VECTOR OR ADENOVIRUS
L2 166 S GP19
L3 9139 S ANTI-CD4
L4 37 S L1 AND L2
L5 0 S L3 AND L4
L6 353896 S IMMUNOSUPPRES?
L7 238 S L3 (9A) L6
L8 194 S L3 (5A) L6
L9 1 S L4 AND L6
L10 13 DUP REM L4 (24 DUPLICATES REMOVED)
L11 96 DUP REM L8 (98 DUPLICATES REMOVED)

=> d au ti so pi ab 19

L9 ANSWER 1 OF 1 LIFESCI COPYRIGHT 2007 CSA on STN
AU Basler, C.F.; Droguett, G.; Horwitz, M.S.
TI Sequence of the immunoregulatory early region 3 and flanking sequences of adenovirus type 35
SO GENE, (1996) vol. 170, no. 2, pp. 249-254.
ISSN: 0378-1119.
AB Adenovirus type 35 (Ad35) is an important pathogen in immunosuppressed individuals such as AIDS patients and bone marrow transplant recipients. Ad35, a member of Ad subgroup B, differs with respect to pathogenic properties from the more fully characterized subgroup C Ad, such as Ad2 and Ad5. One region of human Ad which varies between subgroups and which may influence Ad pathogenesis is early region 3 (E3), a region which appears to modulate the immune response to Ad infection. In order to begin to characterize the differences between the Ad35 E3 and the E3 of other Ad, the complete DNA sequence of the Ad35 E3 promoter and coding sequence along with two flanking structural proteins, pVIII and fiber, has been determined. Ad35 contains open reading frames which are unique to the subgroup B Ad in addition to the four characterized immunoregulatory proteins encoded by the subgroup C Ad. Further evaluation of the sequence of one of these proteins, 18.5K, which is the class-I major histocompatibility complex (MHC) binding protein of 18.5kDa, demonstrates that the amino acid sequence of this Ad2 gp19K homologue fits a proposed model of gp19K-MHC interaction. Analysis of promoter sequences demonstrates that an NF- Kappa B site found in the subgroup C E3 promoter is absent from the Ad35 E3 promoter. In addition, the fiber genes of Ad35 and other subgroup B Ad have been shown to diverge in an unexpected way, yielding three clusters of fiber homology.

=> d au ti so pi 1-13 l10

L10 ANSWER 1 OF 13 MEDLINE on STN DUPLICATE 1
AU Zhu Mingzhu; Bristol J Andrew; Xie Yuefeng; Mina Mervat; Ji Hong;
Forry-Schaudies Suzanne; Ennist David L
TI Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses.
SO Journal of virology, (2005 May) Vol. 79, No. 9, pp. 5455-65.
Journal code: 0113724. ISSN: 0022-538X.

L10 ANSWER 2 OF 13 MEDLINE on STN DUPLICATE 2
AU Lichtenstein Drew L; Toth Karoly; Doronin Konstantin; Tollefson Ann E;
Wold William S M
TI Functions and mechanisms of action of the adenovirus E3

proteins.

- SO International reviews of immunology, (2004 Jan-Apr) Vol. 23, No. 1-2, pp. 75-111. Ref: 179
Journal code: 8712260. ISSN: 0883-0185.

L10 ANSWER 3 OF 13 MEDLINE on STN DUPLICATE 3
AU Wang Yaohe; Hallden Gunnel; Hill Richard; Anand Arthi; Liu Ta-Chiang; Francis Jennelle; Brooks Gabriel; Lemoine Nick; Kirn David
TI E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models.
SO Nature biotechnology, (2003 Nov) Vol. 21, No. 11, pp. 1328-35. Electronic Publication: 2003-10-12.
Journal code: 9604648. ISSN: 1087-0156.

L10 ANSWER 4 OF 13 MEDLINE on STN DUPLICATE 4
AU Hawkins L K; Johnson L; Bauzon M; Nye J A; Castro D; Kitze G A; Young M D; Holt J K; Trown P; Hermiston T W
TI Gene delivery from the E3 region of replicating human adenovirus : evaluation of the 6.7 K/gp19 K region.
SO Gene therapy, (2001 Aug) Vol. 8, No. 15, pp. 1123-31.
Journal code: 9421525. ISSN: 0969-7128.

L10 ANSWER 5 OF 13 MEDLINE on STN DUPLICATE 5
AU Zhou M; Sayad A; Simmons W A; Jones R C; Maika S D; Satumtira N; Dorris M L; Gaskell S J; Bordoli R S; Sartor R B; Slaughter C A; Richardson J A; Hammer R E; Taurog J D
TI The specificity of peptides bound to human histocompatibility leukocyte antigen (HLA)-B27 influences the prevalence of arthritis in HLA-B27 transgenic rats.
SO The Journal of experimental medicine, (1998 Sep 7) Vol. 188, No. 5, pp. 877-86.
Journal code: 2985109R. ISSN: 0022-1007.

L10 ANSWER 6 OF 13 MEDLINE on STN DUPLICATE 6
AU von Herrath M G; Efrat S; Oldstone M B; Horwitz M S
TI Expression of adenoviral E3 transgenes in beta cells prevents autoimmune diabetes.
SO Proceedings of the National Academy of Sciences of the United States of America, (1997 Sep 2) Vol. 94, No. 18, pp. 9808-13.
Journal code: 7505876. ISSN: 0027-8424.

L10 ANSWER 7 OF 13 LIFESCI COPYRIGHT 2007 CSA on STN
AU Schowalter, D.B.; Tubb, J.C.; Liu, M.; Wilson, C.B.; Kay, M.A.*
TI Heterologous expression of adenovirus E3-gp19K in an E1a-deleted adenovirus vector inhibits MHC I expression in vitro, but does not prolong transgene expression in vivo
SO GENE THER., (1997) vol. 4, no. 4, pp. 351-360.
ISSN: 0969-7128.

L10 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 7
AU Sparer, Tim E.; Tripp, Ralph A.; Dillehay, Dirck, L.; Hermiston, Terry W.; Wold, William S. M.; Gooding, Linda R.
TI The role of human adenovirus early region 3 protein (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model
SO Journal of Virology (1996), 70(4), 2431-439
CODEN: JOVIAM; ISSN: 0022-538X

L10 ANSWER 9 OF 13 LIFESCI COPYRIGHT 2007 CSA on STN
AU Basler, C.F.; Droguett, G.; Horwitz, M.S.
TI Sequence of the immunoregulatory early region 3 and flanking sequences of adenovirus type 35
SO GENE, (1996) vol. 170, no. 2, pp. 249-254.
ISSN: 0378-1119.

L10 ANSWER 10 OF 13 LIFESCI COPYRIGHT 2007 CSA on STN
 AU Lee, M.G.; Abina, M.A.; Haddada, H.; Perricaudet, M.
 TI The constitutive expression of the immunomodulatory gp 19k protein in E1-,
 E3- adenoviral vectors strongly reduces the host
 cytotoxic T cell response against the vector
 SO GENE THER., (1995) vol. 2, no. 4, pp. 256-262.
 ISSN: 0969-7128.

L10 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN
 IN Imler, Jean-Luc; Methali, Majid; Pavirani, Andrea
 TI Replication-defective adenoviruses for use in gene therapy and
 complementing cell lines for use in propagation and packaging of the virus
 SO PCT Int. Appl., 82 pp.
 CODEN: PIXXD2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9428152	A1	19941208	WO 1994-FR624	19940527
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2705686	A1	19941202	FR 1993-6482	19930528
FR 2705686	B1	19950818		
CA 2141212	A1	19941208	CA 1994-2141212	19940527
AU 9468503	A	19941220	AU 1994-68503	19940527
EP 652968	A1	19950517	EP 1994-917063	19940527
EP 652968	B1	20010221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07509616	T	19951026	JP 1994-500317	19940527
EP 919624	A2	19990602	EP 1998-124036	19940527
EP 919624	A3	19990818		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
EP 919625	A2	19990602	EP 1998-124037	19940527
EP 919625	A3	19990818		
EP 919625	B1	20020911		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
EP 919626	A2	19990602	EP 1998-124038	19940527
EP 919626	A3	19990818		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
EP 919627	A2	19990602	EP 1998-124039	19940527
EP 919627	A3	19990728		
EP 919627	B1	20000920		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
AT 196502	T	20001015	AT 1998-124039	19940527
ES 2151310	T3	20001216	ES 1998-124039	19940527
PT 919627	T	20001229	PT 1998-124039	19940527
AT 199262	T	20010315	AT 1994-917063	19940527
ES 2155090	T3	20010501	ES 1994-917063	19940527
PT 652968	T	20010731	PT 1994-917063	19940527
EP 1149916	A2	20011031	EP 2001-111931	19940527
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
AT 223968	T	20020915	AT 1998-124037	19940527
PT 919625	T	20021129	PT 1998-124037	19940527
ES 2182212	T3	20030301	ES 1998-124037	19940527
US 6040174	A	20000321	US 1995-379452	19950126
AU 9856251	A	19980507	AU 1998-56251	19980223
AU 710962	B2	19990930		
AU 9941110	A	19990916	AU 1999-41110	19990723
AU 727970	B2	20010104		
US 6133028	A	20001017	US 1999-409670	19990930
GR 3034956	T3	20010228	GR 2000-402659	20001130
US 2001049136	A1	20011206	US 2000-725720	20001130
US 7005277	B2	20060228		
US 2003170885	A1	20030911	US 2000-739007	20001219
US 7067309	B2	20060627		
GR 3035841	T3	20010831	GR 2001-400689	20010509

L10 ANSWER 12 OF 13 MEDLINE on STN DUPLICATE 8
 AU Grunhaus A; Cho S; Horwitz M S
 TI Association of vaccinia virus-expressed adenovirus E3-19K glycoprotein with class I MHC and its effects on virulence in a murine pneumonia model.
 SO Virology, (1994 May 1) Vol. 200, No. 2, pp. 535-46.
 Journal code: 0110674. ISSN: 0042-6822.

L10 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN
 AU Wold, William S. M.; Deutscher, Susan L.; Takemori, Nobuyuki; Bhat, Bheem M.; Magie, Sandra C.
 TI Evidence that AG_UAU_A_U_GA and CC_AAG_A_U_GA initiate translation in the same mRNA in region E3 of adenovirus
 SO Virology (1986), 148(1), 168-80
 CODEN: VIRLAX; ISSN: 0042-6822

=> d au ti so pi 80-96 l11

L11 ANSWER 80 OF 96 MEDLINE on STN
 AU Durham S R
 TI Allergic inflammation.
 SO Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, (1993) Vol. 4, No. 4 Suppl, pp. 7-12. Ref: 47
 Journal code: 9106718. ISSN: 0905-6157.

L11 ANSWER 81 OF 96 CAPLUS COPYRIGHT 2007 ACS on STN
 IN Gorzynski, Timothy James
 TI Improved ascites production of monoclonal antibodies using an immunosuppressive anti-CD4-related antibody
 SO PCT Int. Appl., 34 pp.
 CODEN: PIXXD2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9200100	A1	19920109	WO 1991-US3903	19910607
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
CA 2085586	A1	19911223	CA 1991-2085586	19910607
EP 535084	A1	19930407	EP 1991-911687	19910607
R: DE, FR, IT				
JP 05507851	T	19931111	JP 1991-511477	19910607

L11 ANSWER 82 OF 96 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
 AU BURMESTER G R [Reprint author]; HORNEFF G; EMMRICH F
 TI INTERVENTION WITH IMMUNOMODULATORY AGENTS MONOCLONAL ANTIBODY THERAPY.
 SO Bailliere's Clinical Rheumatology, (1992) Vol. 6, No. 2, pp. 415-434.
 ISSN: 0950-3579.

L11 ANSWER 83 OF 96 SCISEARCH COPYRIGHT (c) 2007 The Thomson Corporation on STN
 AU MANDEL T E (Reprint); KOULMANDA M
 TI THE SURVIVAL OF XENOGRAFTS, ALLOGRAFTS AND ISOGRAFTS IN NOD MICE, AND XENOGRAFTS IN OTHER STRAINS, AFTER IMMUNOSUPPRESSION WITH ANTI-CD4 MONOCLONAL-ANTIBODY
 SO DIABETES NUTRITION & METABOLISM, (1992) Vol. 5, No. 3, Supp. [1], pp. 91-96.
 ISSN: 0394-3402.

L11 ANSWER 84 OF 96 MEDLINE on STN DUPLICATE 32
 AU He Y G; Ross J; Niederkorn J Y
 TI Promotion of murine orthotopic corneal allograft survival by systemic

- administration of anti-CD4 monoclonal antibody.
SO Investigative ophthalmology & visual science, (1991 Sep) Vol. 32, No. 10, pp. 2723-8.
Journal code: 7703701. ISSN: 0146-0404.
- L11 ANSWER 85 OF 96 CAPLUS COPYRIGHT 2007 ACS on STN
AU Ferran, Christiane; Dy, Michel; Sheehan, Kathleen; Schreiber, Robert; Grau, Georges; Bluestone, Jeffrey; Bach, Jean Francois; Chatenoud, Lucienne
TI Cascade modulation by anti-tumor necrosis factor monoclonal antibody of interferon- γ , interleukin 3 and interleukin 6 release after triggering of the CD3/T cell receptor activation pathway
SO European Journal of Immunology (1991), 21(10), 2349-53
CODEN: EJIMAF; ISSN: 0014-2980
- L11 ANSWER 86 OF 96 MEDLINE on STN DUPLICATE 33
AU Honey C R; Charlton H M; Wood K J
TI Rat brain xenografts reverse hypogonadism in mice immunosuppressed with anti-CD4 monoclonal antibody.
SO Experimental brain research. Experimentelle Hirnforschung. Experimentation cerebrale, (1991) Vol. 85, No. 1, pp. 149-52.
Journal code: 0043312. ISSN: 0014-4819.
- L11 ANSWER 87 OF 96 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AU HORNEFF G [Reprint author]; EMMRICH F; KALDEN J R; BURMESTER G R
TI SUPPRESSION OF MONOCYTE-MACROPHAGE ACTIVATION INDUCED BY ANTI-CD4 TREATMENT IN RHEUMATOID ARTHRITIS.
SO Immunitaet und Infektion, (1991) Vol. 19, No. 2, pp. 55-56.
CODEN: IMINDI. ISSN: 0340-1162.
- L11 ANSWER 88 OF 96 CAPLUS COPYRIGHT 2007 ACS on STN
AU Coulombe, M.; Hao, L.; Calcinaro, F.; Gill, R. G.; Eugui, E. M.; Allison, A. C.; Lafferty, K. J.
TI Tolerance induction in adult animals: comparison of RS-61443 and anti-CD4 treatment
SO Transplantation Proceedings (1991), 23(2, Suppl. 2), 31-2
CODEN: TRPPA8; ISSN: 0041-1345
- L11 ANSWER 89 OF 96 LIFESCI COPYRIGHT 2007 CSA on STN
AU Mandel, T.E.; Koulmanda, M.
TI The effect of continuous anti-CD4 monoclonal antibody therapy on fetal pig pancreas xenografts in nonobese diabetic mice.
SO TRANSPLANT. PROC., (1990) vol. 22, no. 5, pp. 2093-2094.
- L11 ANSWER 90 OF 96 MEDLINE on STN DUPLICATE 34
AU Weyand C M; Goronzy J; Swartztrauber K; Fathman C G
TI Immunosuppression by anti-CD4 treatment in vivo. Cellular and humoral responses to alloantigens.
SO Transplantation, (1989 Jun) Vol. 47, No. 6, pp. 1039-42.
Journal code: 0132144. ISSN: 0041-1337.
- L11 ANSWER 91 OF 96 MEDLINE on STN DUPLICATE 35
AU Weyand C M; Goronzy J; Swartztrauber K; Fathman C G
TI Immunosuppression by anti-CD4 treatment in vivo. Persistence of secondary antiviral immune responses.
SO Transplantation, (1989 Jun) Vol. 47, No. 6, pp. 1034-8.
Journal code: 0132144. ISSN: 0041-1337.
- L11 ANSWER 92 OF 96 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AU PIERSON R N III [Reprint author]; WINN H J; RUSSELL P S; AUCHINCLOSS H JR
TI XENOGENEIC SKIN GRAFT REJECTION IS ESPECIALLY DEPENDENT ON CD4 POSITIVE T CELLS.

SO Journal of Experimental Medicine, (1989) Vol. 170, No. 3, pp. 991-996.
CODEN: JEMEAV. ISSN: 0022-1007.

L11 ANSWER 93 OF 96 MEDLINE on STN
AU Hall B M
TI Therapy with monoclonal antibodies to CD4: potential not appreciated?.

SO American journal of kidney diseases : the official journal of the National
Kidney Foundation, (1989 Nov) Vol. 14, No. 5 Suppl 2, pp. 71-7. Ref: 42
Journal code: 8110075. ISSN: 0272-6386.

L11 ANSWER 94 OF 96 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on
STN
AU WEBER W E J [Reprint author]; BURRMAN W A
TI IN-VITRO FUNCTIONAL BLOCKING OF MYELIN BASIC PROTEIN-SPECIFIC CYTOLYTIC
HUMAN T LYMPHOCYTE CLONES BY IMMUNOSUPPRESSIVE DRUGS AND MONOCLONAL
ANTIBODIES.

SO Journal of Neuroimmunology, (1989) Vol. 22, No. 1, pp. 1-10.
CODEN: JNRIDW. ISSN: 0165-5728.

L11 ANSWER 95 OF 96 MEDLINE on STN DUPLICATE 36
AU Carteron N L; Wofsy D; Seaman W E
TI Induction of immune tolerance during administration of monoclonal antibody
to L3T4 does not depend on depletion of L3T4+ cells.

SO Journal of immunology (Baltimore, Md. : 1950), (1988 Feb 1) Vol. 140, No.
3, pp. 713-6.
Journal code: 2985117R. ISSN: 0022-1767.

L11 ANSWER 96 OF 96 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on
STN
AU SEAMAN W E [Reprint author]; GUTSTEIN N; WOFSY D
TI IN-VIVO EFFECTS OF ANTILYMPHOCYTE ANTIBODIES ON IMMUNITY AND AUTOIMMUNITY.

SO Memorias do Instituto Oswaldo Cruz, (1987) Vol. 82, No. SUPPL. II, pp.
117-120.
Meeting Info.: INTERNATIONAL SYMPOSIUM ON IMMUNOMODULATORS: BIOLOGY AND
THERAPEUTIC APPLICATIONS, RIO DE JANEIRO, BRAZIL, APRIL 26-30, 1987. MEM
INST OSWALDO CRUZ RIO J.
CODEN: MIOCAS. ISSN: 0074-0276.

=> d au ti so pi 70-79 111

L11 ANSWER 70 OF 96 MEDLINE on STN DUPLICATE 26
AU Durham S R
TI New insights into the mechanisms of immunotherapy.

SO European archives of oto-rhino-laryngology : official journal of the
European Federation of Oto-Rhino-Laryngological Societies (EUFOS) :
affiliated with the German Society for Oto-Rhino-Laryngology - Head and
Neck Surgery, (1995) Vol. 252 Suppl 1, pp. S64-7. Ref: 27
Journal code: 9002937. ISSN: 0937-4477.

L11 ANSWER 71 OF 96 CAPLUS COPYRIGHT 2007 ACS on STN
AU Powelson, John; Cosimi, A. Benedict
TI The experimental and clinical use in transplantation of monoclonal
antibodies to CD4 and other adhesion molecules

SO Monoclonal Antibodies in Transplantation (1995), 21-52. Editor(s):
Chatenoud, Lucienne. Publisher: Landes, Austin, Tex.
CODEN: 62WNAZ

L11 ANSWER 72 OF 96 MEDLINE on STN DUPLICATE 27
AU Mysliwicz J; Thierfelder S; Mocikat R; Kremmer E
TI Immunological approach to inhibit formation of anti-antibodies to allo-
and xenogeneic anti-T cell immunoglobulin.

SO European journal of immunology, (1994 Oct) Vol. 24, No. 10, pp. 2323-8.
Journal code: 1273201. ISSN: 0014-2980.

L11 ANSWER 73 OF 96 CAPLUS COPYRIGHT 2007 ACS on STN
 AU Steinbruchel, Daniel A.; Nielsen, Bjarne; Kemp, Ejvind
 TI Anti-CD4 monoclonal antibody treatment in combination with total lymphoid irradiation and cyclosporin A in hamster-to-rat cardiac transplantation
 SO APMIS (1994), 102(10), 777-85
 CODEN: APMSEL; ISSN: 0903-4641

L11 ANSWER 74 OF 96 MEDLINE on STN DUPLICATE 28
 AU Looney J E; Willinger A; Lin G; Rieber E P; Riethmuller G; Ghrayeb J
 TI Expression and characterization of cM-T413, a chimeric anti-CD4 antibody with in vitro immunosuppressive activity.
 SO Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy, (1994 Jul) Vol. 16, No. 1, pp. 36-46.
 Journal code: 9418950. ISSN: 1067-5582.

L11 ANSWER 75 OF 96 CAPLUS COPYRIGHT 2007 ACS on STN
 IN Weidle, Ulrich; Scheuer, Werner; Kaluza, Brigitte; Riethmuller, Gert
 TI Synergistic immunosuppressant monoclonal antibody compositions
 SO Ger. Offen., 18 pp.
 CODEN: GWXXBX

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4143214	A1	19930128	DE 1991-4143214	19911230
	WO 9301834	A1	19930204	WO 1992-EP1689	19920723
	W: AU, CA, CS, FI, HU, JP, KR, NO, PL, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	AU 9223788	A	19930223	AU 1992-23788	19920723

L11 ANSWER 76 OF 96 MEDLINE on STN DUPLICATE 29
 AU Markmann J F; Odorico J S; Bassiri H; Desai N; Kim J I; Barker C F
 TI Deletion of donor-reactive T lymphocytes in adult mice after intrathymic inoculation with lymphoid cells.
 SO Transplantation, (1993 Apr) Vol. 55, No. 4, pp. 871-6; discussion 876-7.
 Journal code: 0132144. ISSN: 0041-1337.

L11 ANSWER 77 OF 96 MEDLINE on STN DUPLICATE 30
 AU Wee S; Kawai T; Knowles R; Colvin R; Cosimi A B
 TI Potent CD8+ CTLs detected in anti-CD4 (OKT4A) MAb immunosuppressed cynomolgus recipients with prolonged allograft survival.
 SO Transplantation proceedings, (1993 Feb) Vol. 25, No. 1 Pt 1, pp. 794-5.
 Journal code: 0243532. ISSN: 0041-1345.

L11 ANSWER 78 OF 96 MEDLINE on STN DUPLICATE 31
 AU Pearson T C; Bushell A R; Darby C R; West L J; Morris P J; Wood K J
 TI Lymphocyte changes associated with prolongation of cardiac allograft survival in adult mice using anti-CD4 monoclonal antibody.
 SO Clinical and experimental immunology, (1993 May) Vol. 92, No. 2, pp. 211-7.
 Journal code: 0057202. ISSN: 0009-9104.

L11 ANSWER 79 OF 96 CAPLUS COPYRIGHT 2007 ACS on STN
 AU Pleyer, U.; Rueckert, D. G.; Milani, J. K.; Mondino, B. J.; Schmidt, K. H.; Thiel, H. -J.
 TI Liposome-encapsulated anti-CD4 monoclonal antibodies.
 A new immunosuppressive agent in experimental keratoplasty
 SO Liposomes Ophthalmol. Dermatol. (1993), 79-89. Editor(s): Pleyer, Uwe; Schmidt, Karlheinz; Thiel, Hans-Juergen. Publisher: Hippokrates, Stuttgart, Germany.
 CODEN: 60SMAY

Refine Search

Search Results -

Terms	Documents
L4 near4 L5	35

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L10

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Thursday, March 01, 2007 [Purge Queries](#) [Printable Copy](#) [Create Case](#)

Set Name Query
 side by side

Hit Count Set Name
 result set

DB=PGPB,USPT; PLUR=YES; OP=AND

<u>L10</u>	14 near4 15	35	<u>L10</u>
<u>L9</u>	14 near8 15	80	<u>L9</u>
<u>L8</u>	13 and 15	1	<u>L8</u>
<u>L7</u>	13 and 14	10	<u>L7</u>
<u>L6</u>	12 and 13	21	<u>L6</u>
<u>L5</u>	anti-cd4	4155	<u>L5</u>
<u>L4</u>	immunosuppres\$	32119	<u>L4</u>
<u>L3</u>	11 with L2	21	<u>L3</u>
<u>L2</u>	gp19	87	<u>L2</u>
<u>L1</u>	adenoviral adj vector or adenovirus	46639	<u>L1</u>

END OF SEARCH HISTORY

Generate Collection

Print

Search Results - Record(s) 1 through 20 of 21 returned.

-
- ☐ 1. [20050136035](#). 01 Jun 04. 23 Jun 05. Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site. Ko, Derek, et al. 424/93.2; 435/366 435/456 A61K048/00 C12N015/861 C12N005/08.
-
- ☐ 2. [20050095705](#). 14 Apr 04. 05 May 05. Method for production of oncolytic adenoviruses. Kadan, Michael, et al. 435/367; 435/456 C12N005/08 C12N015/86.
-
- ☐ 3. [20030215432](#). 11 Mar 03. 20 Nov 03. Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues. Matalon, Reuben. 424/94.61; A61K038/47.
-
- ☐ 4. [20030170885](#). 19 Dec 00. 11 Sep 03. Defective adenoviruses and corresponding complementation lines. Imler, Jean-Luc, et al. 435/320.1; 424/93.21 435/235.1 A61K048/00 C12N007/01 C12N015/861.
-
- ☐ 5. [20030148520](#). 21 Mar 01. 07 Aug 03. Cell-specific adenovirus vectors comprising an internal ribosome entry site. Yu, De-Chao, et al. 435/456; 424/93.2 435/235.1 435/320.1 C12N015/861 C12N007/00 A61K048/00.
-
- ☐ 6. [20030104625](#). 22 Feb 02. 05 Jun 03. Novel oncolytic adenoviral vectors. Cheng, Cheng, et al. 435/456; 435/199 435/235.1 435/320.1 C12N015/861 C12N009/22 C12N007/00.
-
- ☐ 7. [20030068307](#). 21 Mar 01. 10 Apr 03. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation. Yu, De-Chao, et al. 424/93.21; 424/649 424/85.7 514/110 514/12 514/171 514/251 514/263.38 514/27 514/34 514/50 A61K048/00 A61K038/21 A61K031/7048 A61K033/24.
-
- ☐ 8. [20020192185](#). 14 Jan 02. 19 Dec 02. Recombinant protein production in bovine adenovirus expression vector system. Mittal, Suresh K., et al. 424/93.2; 424/199.1 424/233.1 435/235.1 435/320.1 435/456 A61K048/00 A61K039/235 C12N007/00 C12N015/861 A01N063/00 A61K039/23 C12N007/01 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74 C12N015/86 A61K039/12.
-
- ☐ 9. [7067309](#). 19 Dec 00; 27 Jun 06. Defective adenoviruses and corresponding complementation lines. Imler, Jean-Luc, et al. 435/320.1; 424/93.2 435/455 435/456. A61K48/00 20060101 C12N15/09 20060101 C12N15/861 20060101 .
-
- ☐ 10. [7025967](#). 14 Jan 02; 11 Apr 06. Recombinant protein production in bovine adenovirus expression vector system. Mittal, Suresh K., et al. 424/199.1; 424/93.2 435/235.1 435/320.1 435/455 435/456. A61K39/235 20060101 A61K39/295 20060101 C12N15/861 20060101 C12N7/01 20060101 .
-
- ☐ 11. [6911200](#). 21 Mar 01; 28 Jun 05. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation. Yu, De-Chao, et al. 424/93.2; 435/320.1 435/455 435/456. A01N063/00 A61K048/00 C12N015/861 .
-
- ☐ 12. [6852528](#). 21 Mar 01; 08 Feb 05. Human and mouse uroplakin II gene transcriptional regulatory elements. Yu, De-Chao, et al. 435/320.1; 435/235.1 435/455 435/6 435/69.1 435/69.7 514/44 536/23.1 536/23.4 536/24.1. C12N015/861 C12N015/00 C12N007/00 A61K035/76 C07H021/04 .
-
- ☐ 13. [6692736](#). 21 Mar 01; 17 Feb 04. Cell-specific adenovirus vectors comprising an internal ribosome entry site. Yu, De-Chao, et al. 424/93.2; 435/235.1 435/320.1 435/369 435/375 435/457 435/69.1 435/91.4 435/91.41 435/91.42

514/44. C12P021/06 C12P007/00 C12P015/00 C12N005/10 C12N007/02 C12N015/86 .

☐ 14. [6495130](#). 29 Dec 99; 17 Dec 02. Target cell-specific adenoviral vectors containing E3 and methods of use thereof. Henderson; Daniel R., et al. 424/93.2; 424/93.1 424/93.6 435/320.1 435/325 435/455 514/44. A61K353/00 A61K048/00 C12N015/63 C12N015/85 C12N015/09 .

☐ 15. [6491909](#). 01 Aug 00; 10 Dec 02. Attenuation of rejected cells transformed with adenovirus E3. Brownlee; Michael, et al. 424/93.21; 424/93.2 435/325 435/455 435/456 514/44. A61K048/00 A01N063/00 C12N015/00 C12N005/00 .

☐ 16. [6379944](#). 05 Nov 99; 30 Apr 02. Mammalian cell lines expressing bovine adenovirus functions. Mittal; Suresh K., et al. 435/235.1; 435/325 435/455. C12N007/00 C12N005/10 C12N015/00 C12N007/01 .

☐ 17. [6319716](#). 23 Jun 98; 20 Nov 01. Bovine adenovirus type 3 genome and vector systems derived therefrom. Tikoo; Suresh Kumar, et al. 435/471; 424/199.1 424/93.2 435/235.1 435/320.1 435/472 435/475 435/477. C12N015/181 C12N015/64 .

☐ 18. [6156306](#). 16 Oct 96; 05 Dec 00. Pancreatic .beta.-cells for allogeneic transplantation without immunosuppression. Brownlee; Michael, et al. 424/93.21; 435/320.1 435/325 435/455 435/456 435/69.1 514/44 536/23.1 536/23.5. A01N043/04 A61K031/70 C12N015/00 C12N015/63 .

☐ 19. [6040174](#). 26 Jan 95; 21 Mar 00. Defective adenoviruses and corresponding complementation lines. Imler; Jean-Luc, et al. 435/325; 424/93.2 435/320.1 435/456. C12N005/10 C12N015/86 C12N015/34 .

☐ 20. [6001591](#). 25 Apr 97; 14 Dec 99. Recombinant bovine adenoviruses. Mittal; Suresh K., et al. 435/69.1; 424/199.1 435/235.1 435/320.1. C12N015/00 C12N007/01 C12N015/86 .

[Generate Collection](#)

[Print](#)

Terms	Documents
L2 and L3	21

[Prev Page](#)

[Next Page](#)

[Go to Doc#](#)

Generate Collection

Print

Search Results - Record(s) 1 through 10 of 10 returned.

- ☐ 1. [20050136035](#). 01 Jun 04. 23 Jun 05. Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site. Ko, Derek, et al. 424/93.2; 435/366 435/456 A61K048/00 C12N015/861 C12N005/08.
- ☐ 2. [20030148520](#). 21 Mar 01. 07 Aug 03. Cell-specific adenovirus vectors comprising an internal ribosome entry site. Yu, De-Chao, et al. 435/456; 424/93.2 435/235.1 435/320.1 C12N015/861 C12N007/00 A61K048/00.
- ☐ 3. [20030104625](#). 22 Feb 02. 05 Jun 03. Novel oncolytic adenoviral vectors. Cheng, Cheng, et al. 435/456; 435/199 435/235.1 435/320.1 C12N015/861 C12N009/22 C12N007/00.
- ☐ 4. [20030068307](#). 21 Mar 01. 10 Apr 03. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation. Yu, De-Chao, et al. 424/93.21; 424/649 424/85.7 514/110 514/12 514/171 514/251 514/263.38 514/27 514/34 514/50 A61K048/00 A61K038/21 A61K031/7048 A61K033/24.
- ☐ 5. [6911200](#). 21 Mar 01; 28 Jun 05. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation. Yu; De-Chao, et al. 424/93.2; 435/320.1 435/455 435/456. A01N063/00 A61K048/00 C12N015/861 .
- ☐ 6. [6852528](#). 21 Mar 01; 08 Feb 05. Human and mouse uroplakin II gene transcriptional regulatory elements. Yu; De-Chao, et al. 435/320.1; 435/235.1 435/455 435/6 435/69.1 435/69.7 514/44 536/23.1 536/23.4 536/24.1. C12N015/861 C12N015/00 C12N007/00 A61K035/76 C07H021/04 .
- ☐ 7. [6692736](#). 21 Mar 01; 17 Feb 04. Cell-specific adenovirus vectors comprising an internal ribosome entry site. Yu; De-Chao, et al. 424/93.2; 435/235.1 435/320.1 435/369 435/375 435/457 435/69.1 435/91.4 435/91.41 435/91.42 514/44. C12P021/06 C12P007/00 C12P015/00 C12N005/10 C12N007/02 C12N015/86 .
- ☐ 8. [6495130](#). 29 Dec 99; 17 Dec 02. Target cell-specific adenoviral vectors containing E3 and methods of use thereof. Henderson; Daniel R., et al. 424/93.2; 424/93.1 424/93.6 435/320.1 435/325 435/455 514/44. A61K353/00 A61K048/00 C12N015/63 C12N015/85 C12N015/09 .
- ☐ 9. [6491909](#). 01 Aug 00; 10 Dec 02. Attenuation of rejected cells transformed with adenovirus E3. Brownlee; Michael, et al. 424/93.21; 424/93.2 435/325 435/455 435/456 514/44. A61K048/00 A01N063/00 C12N015/00 C12N005/00 .
- ☐ 10. [6156306](#). 16 Oct 96; 05 Dec 00. Pancreatic .beta.-cells for allogeneic transplantation without immunosuppression. Brownlee; Michael, et al. 424/93.21; 435/320.1 435/325 435/455 435/456 435/69.1 514/44 536/23.1 536/23.5. A01N043/04 A61K031/70 C12N015/00 C12N015/63 .

Generate Collection

Print

Terms	Documents
L3 and L4	10

[Prev Page](#) [Next Page](#) [Go to Doc#](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 1 of 1 returned.**

☐ 1. [6495130](#). 29 Dec 99; 17 Dec 02. Target cell-specific adenoviral vectors containing E3 and methods of use thereof. Henderson; Daniel R., et al. 424/93.2; 424/93.1 424/93.6 435/320.1 435/325 435/455 514/44. A61K353/00 A61K048/00 C12N015/63 C12N015/85 C12N015/09 .

[Generate Collection](#)[Print](#)

Terms	Documents
L3 and L5	1

[Prev Page](#)[Next Page](#)[Go to Doc#](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 21 through 35 of 35 returned.**

-
- ☐ 21. [6596770](#). 11 Jan 02; 22 Jul 03. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor. Lai; Ching-San, et al. 514/599; 514/357 514/408 514/706 514/707 514/851. A61K031/16 A61K031/095 A61K031/105 .
-
- ☐ 22. [6589991](#). 05 May 00; 08 Jul 03. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor. Lai; Ching-San, et al. 514/599;. A61K031/16 .
-
- ☐ 23. [6316502](#). 05 May 00; 13 Nov 01. Therapeutic methods employing disulfide derivatives of dithiocarbonates and compositions useful therefor. Lai; Ching-San, et al. 514/599; 514/707 514/825 514/838 514/851 514/861 514/866 514/885 514/903 514/912 514/925. A01N037/18 .
-
- ☐ 24. [6143273](#). 13 Apr 98; 07 Nov 00. Therapeutic composition containing antibodies to soluble polypeptide fractions of LAG-3 protein. Faure; Florence, et al. 424/1.49; 424/139.1 424/143.1 424/152.1 530/387.2 530/387.9 530/388.7 530/388.73 530/389.6 530/391.3. A61K051/00 A61K039/395 C07K016/28 .
-
- ☐ 25. [6093743](#). 23 Jun 98; 25 Jul 00. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor. Lai; Ching-San, et al. 514/599; 514/706 514/707 514/851 514/861 514/863 514/866 514/909 514/912. A61K031/16 A61K031/095 A61K031/105 .
-
- ☐ 26. [6004554](#). 02 Dec 94; 21 Dec 99. Methods for targeting the vasculature of solid tumors. Thorpe; Philip E., et al. 424/178.1; 424/136.1 424/181.1 424/182.1 424/183.1. A61K039/395 A61K039/40 A61K039/42 .
-
- ☒ 27. [5958409](#). 13 Mar 96; 28 Sep 99. Method for treating multiple sclerosis. Turk; John Leslie, et al. 424/141.1; 424/145.1 424/156.1 514/2 530/350. A61K039/395 A61K038/00 .
-
- ☐ 28. [5955300](#). 24 Dec 96; 21 Sep 99. Soluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotypic antibodies. Faure; Florence, et al. 435/69.1; 435/455 530/324 530/330 530/350 530/391.3 530/391.7. C12P021/00 C12N015/09 A61K038/07 A61K038/16 .
-
- ☐ 29. [5912005](#). 19 Nov 96; 15 Jun 99. Methods of use of uncoated gel particles. Lanza; Robert P., et al. 424/424; 424/422 424/423 435/174 435/177 435/243 435/382 514/866 514/885 514/907 514/953. C12N011/04 A61K009/52 .
-
- ☐ 30. [5871732](#). 27 Nov 91; 16 Feb 99. Anti-CD4 antibody homologs useful in prophylaxis and treatment of AIDS, ARC and HIV infection. Burkly; Linda C., et al. 424/133.1; 424/143.1 424/154.1 530/387.3 530/388.75. C12P021/08 A61K039/395 C08G075/14 .
-
- ☐ 31. [5651980](#). 15 Apr 94; 29 Jul 97. Methods of use of uncoated gel particles. Lanza; Robert P., et al. 424/424; 424/422 424/423 435/174 435/177 435/243 435/382 514/866 514/885 514/907 514/953. C12N011/04 A61K009/52 .
-
- ☐ 32. [RE35450](#). 14 Jun 93; 11 Feb 97. Soluble human interleukin-1 receptors, compositions and method of use. Dower; Steven K., et al. 530/351; 424/85.1 424/85.2 435/69.1 435/69.5 435/69.52 530/345 530/350 530/387.1 930/141. C07K013/00 .
-
- ☐ 33. [5492888](#). 17 Jun 92; 20 Feb 96. Method of using soluble human interleukin-1 receptors to suppress immune responses. Dower; Steven K., et al. 514/2; 424/85.2 514/12 514/21 514/8 514/885. A61K038/16 C07K014/705 .
-

☐ 34. 5488032. 17 Jun 92; 30 Jan 96. Method of using soluble human interleukin-1 receptors to suppress inflammation. Dower; Steven K., et al. 514/2; 424/85.2 514/12 514/21 514/8 514/886. A61K038/16 C07K014/705 .

☐ 35. 5180812. 21 Dec 89; 19 Jan 93. Soluble human interleukin-1 receptors, compositions and method of use. Dower; Steven K., et al. 530/351; 424/85.1 424/85.2 435/69.1 435/69.5 435/69.52 530/350 530/387.1 530/395 930/141. C07K013/00 .

[Generate Collection](#)[Print](#)

Terms	Documents
L4 near4 L5	35

[Prev Page](#)[Next Page](#)[Go to Doc#](#)